Spironolactone Tablet, Film Coated
Product Images NDC 70518-0665

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 70518-0665). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Spironolactone 100 mg tablets, film-coated, containing 30 tablets. The label includes storage instructions and notes that the product is repackaged by RemedyRepack Inc., Indiana, PA. Manufacturer details (Cadista Pharma) and NDC 70518-0665-01 are visible. Tablets are described as round brown.*

FDA Label Image

Spironolactone 100mg 70518 0665 00

Spironolactone Tablet 100 mg film-coated tablets, packaged in a quantity of 30 tablets. The label states the NDC number 70518-0665-00 and indicates the tablets are round and brown. The product is repackaged by RemedyRepack Inc., Indiana, PA. Storage and handling instructions include protection from light and temperature recommendations.*

FDA Label Image

Structure

Chemical structure diagram of spironolactone, the active ingredient in Spironolactone 100 mg film-coated tablets by RemedyRepack Inc. The structure shows multiple cyclic rings with specific functional groups including a ketone and a thioester.*

FDA Label Image

Figure 1

A Kaplan-Meier survival curve chart comparing the probability over time in months between Spironolactone (solid line, n=822) and placebo (dashed line, n=841) groups. The chart shows a statistically significant difference (Log-rank p < 0.001) in survival probability favoring Spironolactone.*

FDA Label Image

Figure 2

A forest plot displaying hazard ratios and 95% confidence intervals for various subgroups comparing spironolactone to placebo. Subgroups include age, sex, race, left ventricular ejection fraction, heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, and use of digoxin, ACE inhibitors, and beta blockers. The plot visually shows the relative effect of spironolactone versus placebo for each subgroup.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.